Report ID: SQMIG30I2371
Report ID:
SQMIG30I2371 |
Region:
Global |
Published Date: June, 2024
Pages:
198
|
Tables:
143 |
Figures:
70
In October 2023, SPI Pharma, Inc. (SPI) and Q-Vant Biosciences, Inc. (Q-Vant) partnered to leverage Q-Vant's leadership in unique, sustainable saponin extraction technology with SPI's global pharmaceutical reach and expertise in servicing the industry. Q-Vant has over a decade of saponin purification and sustainable Quillaja sourcing experience, combined with installed sustainable and scalable biomass technology as well as significant investments in high-density plantations, cell culture technology and greenhouses.
In August 2023, Botanical Solution Inc. (BSI), the multiple award-winning innovators of sustainable, highly consistent and cost effective Advanced Botanical Materials (ABM), secured an additional $7 million investment. ABM-01 is the first ABM produced by the company, based on a plant called Quillaja saponaria.
In May 2023, Croda Pharma entered a strategic collaboration deal with Botanical Solution Inc (BSI) to expedite the production of sustainable pharmaceutical-grade vaccine adjuvant QS-21. Croda Pharma and BSI will share their knowledge to bring QS-21 to market from quillaja Saponaria plant cell culture, which is made from the soap bark tree.
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATIONWant to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Report ID: SQMIG30I2371